Reported Earnings • Jun 25
Full year 2025 earnings released: UK£0.008 loss per share (vs UK£0.009 loss in FY 2024) Full year 2025 results: UK£0.008 loss per share. Net loss: UK£5.09m (loss widened 35% from FY 2024). Duyuru • Jun 09
Tern Plc, Annual General Meeting, Jun 30, 2026 Tern Plc, Annual General Meeting, Jun 30, 2026. Location: the offices of allenby capital, 5 st helens place, ec3a 6ab, london United Kingdom Duyuru • May 20
Tern Plc has completed a Follow-on Equity Offering in the amount of £0.222 million. Tern Plc has completed a Follow-on Equity Offering in the amount of £0.222 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 37,000,000
Price\Range: £0.006
Transaction Features: Subsequent Direct Listing Duyuru • May 08
Tern Plc has completed a Follow-on Equity Offering in the amount of £0.405998 million. Tern Plc has completed a Follow-on Equity Offering in the amount of £0.405998 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 67,666,314
Price\Range: £0.006
Transaction Features: Rights Offering Duyuru • Mar 03
Tern Plc has completed a Follow-on Equity Offering in the amount of £0.312655 million. Tern Plc has completed a Follow-on Equity Offering in the amount of £0.312655 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 78,163,662
Price\Range: £0.004
Transaction Features: Rights Offering Duyuru • Feb 13
Tern Plc has filed a Follow-on Equity Offering in the amount of £0.384408 million. Tern Plc has filed a Follow-on Equity Offering in the amount of £0.384408 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 96,101,957
Price\Range: £0.004
Transaction Features: Rights Offering Duyuru • Oct 01
Tern Plc has filed a Follow-on Equity Offering in the amount of £0.642486 million. Tern Plc has filed a Follow-on Equity Offering in the amount of £0.642486 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 128,497,293
Price\Range: £0.005
Transaction Features: Rights Offering Duyuru • Jul 30
Tern Plc has completed a Follow-on Equity Offering in the amount of £0.642486 million. Tern Plc has completed a Follow-on Equity Offering in the amount of £0.642486 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 64,248,646
Price\Range: £0.01
Discount Per Security: £0.0009
Transaction Features: Rights Offering Duyuru • Jul 14
Tern Plc has filed a Follow-on Equity Offering in the amount of £0.642486 million. Tern Plc has filed a Follow-on Equity Offering in the amount of £0.642486 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 64,248,646
Price\Range: £0.01
Discount Per Security: £0.0009
Transaction Features: Rights Offering Duyuru • Jun 30
Tern Plc Appoints Jane Mccracken as Interim Chair Tern Plc announced that Jane McCracken, previously an independent Non-Executive Director of the Company, assumed the role of the Company's Chair at the conclusion of the AGM, initially on an interim basis. The Board of the Company now therefore comprises Jane McCracken (Independent Interim Non-Executive Chair) and Iain Ross (Independent Non-Executive Director). The Board will continue to be supported by a non-Board senior management team, led by Al Sisto and Bruce Leith. Duyuru • Jun 07
Tern Plc, Annual General Meeting, Jun 30, 2025 Tern Plc, Annual General Meeting, Jun 30, 2025. Location: the offices of allenby capital, 5 st helens place, ec3a 6ab, london United Kingdom Duyuru • Jun 06
Tern PLC Announces Ian Ritchie Decides to Retire from its Board, Effective June 30, 2025 Tern PLC announced that Ian Ritchie, who has been the Company's Non-Executive Chairman since 2017, has decided to retire from the Board at the conclusion of the AGM to be held on June 30, 2025. Duyuru • May 07
Tern Plc has completed a Follow-on Equity Offering in the amount of £0.34014 million. Tern Plc has completed a Follow-on Equity Offering in the amount of £0.34014 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 34,013,989
Price\Range: £0.01
Transaction Features: Rights Offering Duyuru • Apr 17
Tern Plc has filed a Follow-on Equity Offering in the amount of £0.34014 million. Tern Plc has filed a Follow-on Equity Offering in the amount of £0.34014 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 34,013,989
Price\Range: £0.01
Transaction Features: Rights Offering Duyuru • Feb 26
Tern Plc has completed a Follow-on Equity Offering in the amount of £0.221154 million. Tern Plc has completed a Follow-on Equity Offering in the amount of £0.221154 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 19,230,769
Price\Range: £0.0115
Transaction Features: Subsequent Direct Listing Duyuru • Feb 21
Tern Plc has filed a Follow-on Equity Offering in the amount of £0.221154 million. Tern Plc has filed a Follow-on Equity Offering in the amount of £0.221154 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 19,230,769
Price\Range: £0.0115
Transaction Features: Subsequent Direct Listing Duyuru • Dec 16
Tern Plc has completed a Follow-on Equity Offering in the amount of £0.4 million. Tern Plc has completed a Follow-on Equity Offering in the amount of £0.4 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 30,769,231
Price\Range: £0.013
Transaction Features: Subsequent Direct Listing Board Change • Nov 04
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chairman Ian Ritchie was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Oct 30
Tern plc Announces Board Changes Tern Plc announced a number of changes to the Company's Board of Directors (the "Board"). Tern announced the appointment of Jane Karwoski (known as "Jane McCracken") and Iain Ross as independent Non-Executive Directors of the Company with immediate effect. Sarah Payne and Alan Howarth have stepped down from the Board with immediate effect to concentrate on their other business interests. Following these changes the Board now comprises Ian Ritchie (Non-Executive Chairman), Jane McCracken (Non-Executive Director) and Iain Ross (Non-Executive Director). Jane McCracken has spent her career working with high growth technology businesses based in the USA. UK and Europe as an entrepreneur, investor, board member and advisor. Her experience covers a variety of areas including software, e-commerce, digital health and clinical research. She recently served as an Entrepreneur-in-Residence at the Advanced Technology Development Center, the state incubator based at Georgia Institute of Technology. She is the Chief Growth Officer for Corps Team, a US-based search and staffing firm supporting startups to the Fortune 500. Jane also serves on the board of London Stock Exchange Main Market listed Edinburgh Worldwide Investment Trust plc, which invests globally in high growth companies; and Radyus Research, a US-based privately held company that advises on drug discovery, lead candidate selection, and enabling studies. Iain Ross has over 40 years' experience in the international life sciences and technology sectors and has held significant roles in multi-national pharmaceutical and biotech companies. He has completed multiple financing transactions and has over 30 years' experience in cross-border management as a chairman or CEO. He has led or participated in eight IPOs and has direct experience of M&A transactions in Europe, the USA and the Pacific Rim. Currently he is Chairman of NASDAQ listed Silence Therapeutics plc, Executive Chairman of ReNeuron Group plc and internationally holds other non-executive director roles. Iain Ross joined the board of Redx Pharma plc on 1 May 2017. On 24 May 2017, Redx Pharma plc and Redx Oncology Ltd. were put into administration by Liverpool City Council, whilst Iain Ross was a director of both companies, as a result of non-payment of an outstanding loan of £2m. On 3 November 2017 Redx Pharma plc and Redx Oncology Ltd. exited administration with all creditors paid, under the Chairmanship of Iain Ross.Iain Ross was a director of Palla Pharma Limited, a company registered in Tasmania Australia, when it entered into administration on 17 December 2021. Subsequently in March 2022, a liquidator was appointed for a creditors' voluntary liquidation process. Iain Ross resigned from the board of Palla Pharma Limited on 20 April 2022. Iain Ross is Chairman of ReNeuron Group plc and director of its three subsidiaries, ReNeuron (UK) Limited, ReNeuron Holdings Limited, ReNeuron Limited, all of which entered into administration on 20 March 2024. This process is currently ongoing and Iain Ross remains the Chairman of ReNeuron Group plc and a director of the three above subsidiaries. New Risk • Sep 06
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£1.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.0m free cash flow). Share price has been highly volatile over the past 3 months (374% average daily change). Earnings have declined by 60% per year over the past 5 years. Revenue is less than US$1m (UK£41k revenue, or US$54k). Market cap is less than US$10m (€6.41m market cap, or US$7.12m). Minor Risk Shareholders have been diluted in the past year (11% increase in shares outstanding). Reported Earnings • Jun 04
Full year 2023 earnings released: UK£0.032 loss per share (vs UK£0.029 loss in FY 2022) Full year 2023 results: UK£0.032 loss per share (further deteriorated from UK£0.029 loss in FY 2022). Net loss: UK£12.6m (loss widened 21% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 30 percentage points per year, which is a significant difference in performance. Duyuru • May 31
Tern Plc, Annual General Meeting, Jun 27, 2024 Tern Plc, Annual General Meeting, Jun 27, 2024. Location: the offices of allenby capital, 5 st helens place, ec3a 6ab, london United Kingdom Buy Or Sell Opportunity • Apr 26
Now 99% overvalued after recent price rise Over the last 90 days, the stock has risen 36% to €0.022. The fair value is estimated to be €0.011, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.6% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Mar 28
Now 71% overvalued Over the last 90 days, the stock has fallen 24% to €0.015. The fair value is estimated to be €0.0091, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.6% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Mar 12
Now 37% overvalued Over the last 90 days, the stock has fallen 57% to €0.012. The fair value is estimated to be €0.0088, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.6% over the last 3 years. Meanwhile, the company became loss making. New Risk • Mar 03
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (53% average daily change). Earnings have declined by 41% per year over the past 5 years. Revenue is less than US$1m (UK£202k revenue, or US$256k). Market cap is less than US$10m (€9.09m market cap, or US$9.85m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (5.4% increase in shares outstanding). New Risk • Mar 01
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €9.09m (US$9.83m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (53% average daily change). Earnings have declined by 41% per year over the past 5 years. Revenue is less than US$1m (UK£202k revenue, or US$255k). Market cap is less than US$10m (€9.09m market cap, or US$9.83m). Minor Risk Shareholders have been diluted in the past year (5.4% increase in shares outstanding). Buy Or Sell Opportunity • Feb 08
Now 74% overvalued Over the last 90 days, the stock has fallen 53% to €0.018. The fair value is estimated to be €0.01, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.6% over the last 3 years. Meanwhile, the company became loss making. New Risk • Jan 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (58% average weekly change). Earnings have declined by 41% per year over the past 5 years. Revenue is less than US$1m (UK£202k revenue, or US$257k). Minor Risks Shareholders have been diluted in the past year (5.4% increase in shares outstanding). Market cap is less than US$100m (€9.84m market cap, or US$10.7m). Duyuru • Jan 26
Tern Plc has completed a Follow-on Equity Offering in the amount of £0.4 million. Tern Plc has completed a Follow-on Equity Offering in the amount of £0.4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 20,000,000
Price\Range: £0.02
Transaction Features: Subsequent Direct Listing Buy Or Sell Opportunity • Jan 23
Now 111% overvalued Over the last 90 days, the stock has fallen 36% to €0.024. The fair value is estimated to be €0.011, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.6% over the last 3 years. Meanwhile, the company became loss making. New Risk • Dec 29
New major risk - Revenue and earnings growth Earnings have declined by 41% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£2.0m free cash flow). Share price has been highly volatile over the past 3 months (35% average weekly change). Earnings have declined by 41% per year over the past 5 years. Revenue is less than US$1m (UK£202k revenue, or US$257k). Minor Risk Market cap is less than US$100m (€15.1m market cap, or US$16.7m). New Risk • Dec 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (32% average weekly change). Revenue is less than US$1m (UK£66k revenue, or US$84k). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (€19.3m market cap, or US$21.0m). Reported Earnings • Jun 01
Full year 2022 earnings released: UK£0.029 loss per share (vs UK£0.013 profit in FY 2021) Full year 2022 results: UK£0.029 loss per share (down from UK£0.013 profit in FY 2021). Net loss: UK£10.4m (down 328% from profit in FY 2021). Duyuru • May 31
Tern Plc, Annual General Meeting, Jun 29, 2023 Tern Plc, Annual General Meeting, Jun 29, 2023, at 08:00 Coordinated Universal Time. Location: Reed Smith, The Broadgate Tower, 20 Primrose Street London United Kingdom Duyuru • May 23
Tern Plc to Report Fiscal Year 2022 Final Results on May 31, 2023 Tern Plc announced that they will report fiscal year 2022 final results on May 31, 2023 Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Chairman & Senior Independent Director Ian Ritchie was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 24
First half 2022 earnings released: UK£0.007 loss per share (vs UK£0.002 loss in 1H 2021) First half 2022 results: UK£0.007 loss per share (further deteriorated from UK£0.002 loss in 1H 2021). Net loss: UK£2.41m (loss widened 236% from 1H 2021). Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Chairman & Senior Independent Director Ian Ritchie was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 18
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: UK£0.014 (up from UK£0.003 in FY 2020). Revenue: UK£6.10m (up UK£5.95m from FY 2020). Net income: UK£4.58m (up 470% from FY 2020). Profit margin: 75% (down from 532% in FY 2020). The decrease in margin was primarily driven by higher revenue. Revenue was in line with analyst estimates. Reported Earnings • Sep 16
First half 2021 earnings released: UK£0.002 loss per share (vs UK£0.001 profit in 1H 2020) First half 2021 results: Net loss: UK£718.5k (down UK£860.9k from profit in 1H 2020). 
